KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Debt to Equity: 2020-2025

Historic Debt to Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $0.02.

  • Recursion Pharmaceuticals' Debt to Equity fell 63.69% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 63.69%. This contributed to the annual value of $0.03 for FY2024, which is 976.39% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Debt to Equity of $0.02 as of Q3 2025, which was down 20.34% from $0.02 recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Debt to Equity peaked at $0.05 during Q3 2024, and registered a low of -$0.04 during Q1 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Debt to Equity averaged around $0.02, with its median value being $0.02 (2025).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Debt to Equity slumped by 90.87% in 2022, and later soared by 2,055.72% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.00 in 2021, then dropped by 5.37% to $0.00 in 2022, then spiked by 123.34% to $0.00 in 2023, then skyrocketed by 976.39% to $0.03 in 2024, then plummeted by 63.69% to $0.02 in 2025.
  • Its Debt to Equity stands at $0.02 for Q3 2025, versus $0.02 for Q2 2025 and $0.03 for Q1 2025.